Poulvac Marek CVI

Šalis: Didžioji Britanija

kalba: anglų

Šaltinis: VMD (Veterinary Medicines Directorate)

Veiklioji medžiaga:

Marek's disease virus

Prieinama:

Zoetis UK Limited

ATC kodas:

QI01AD03

INN (Tarptautinis Pavadinimas):

Marek's disease virus

Vaisto forma:

Powder and solvent for suspension for injection

Recepto tipas:

POM-VPS -Prescription Only Medicine – Veterinarian, Pharmacist, Suitably Qualified Person

Farmakoterapinė grupė:

Chickens

Gydymo sritis:

Live Viral Vaccine

Autorizacija statusas:

Authorized

Leidimo data:

2005-10-28

Prekės savybės

Revised: July 2022
AN: 02480/2021
Page 1 of 6
SUMMARY OF PRODUCT CHARACTERISTICS
1.
NAME OF THE VETERINARY MEDICINAL PRODUCT
Poulvac Marek CVI.
(To be suspended in Poulvac Marek Diluent)
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
One dose of 0.2 ml contains:
ACTIVE SUBSTANCE:
Live Marek’s disease virus (MDV), strain CVI 988, cell associated:

250
CCID
50
*
*CCID
50
= 50 % cell culture infective dose
EXCIPIENT(S):
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Frozen virus-infected cell suspension and diluent for suspension for
injection.
4.
CLINICAL PARTICULARS
4.1
TARGET SPECIES
One day old chickens.
4.2
INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
For the active immunisation of chickens to reduce mortality and
lesions caused
by Marek’s Disease.
The onset of immunity is from 9 days of vaccination and the duration
of
immunity is not known but has been shown by challenge to be at least 4
weeks. Vaccine virus and antibodies to Marek’s disease virus have
been
shown to persist in vaccinated chickens for up to 2 years.
4.3
CONTRAINDICATIONS
Do not use in sick chickens.
Revised: July 2022
AN: 02480/2021
Page 2 of 6
4.4
SPECIAL WARNINGS
Vaccine virus spreads from bird to bird. In a study in highly
susceptible Rhode
Island Red birds, vaccine virus was shown to increase in virulence
after ten
passages.
Maternally derived antibody (MDA) can interfere with the development
of active
immunity. Where it is likely that recent field infection or
vaccination of the
parent flock has stimulated a high antibody titre and consequently a
high level
of MDA, the timing of the vaccination programme should be planned
accordingly.
4.5
SPECIAL PRECAUTIONS FOR USE, INCLUDING SPECIAL PRECAUTIONS TO BE TAKEN
BY
THE PERSON ADMINISTERING THE MEDICINAL PRODUCT TO ANIMALS
i.
Special precautions for use in animals
Avoid stress in chickens before and after vaccination.
Avoid injection into or near joints and tendons.
ii.
Special precautions to be taken by the person administering the
veterinary medicinal pro